Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Quoin Pharmaceuticals ( (QNRX) ).
Quoin Pharmaceuticals Ltd. has announced that its 2025 Annual General Meeting of Shareholders will be held on August 21, 2025, which is more than 30 days earlier than the previous year’s meeting. As a result, the company has updated the deadlines for shareholder proposals and proxy solicitations, requiring submissions by June 30, 2025, to ensure timely inclusion in the proxy materials.
The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.
Spark’s Take on QNRX Stock
According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.
Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.
To see Spark’s full report on QNRX stock, click here.
More about Quoin Pharmaceuticals
Average Trading Volume: 291,240
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.94M
Learn more about QNRX stock on TipRanks’ Stock Analysis page.